ALX Oncology Extends Cash Runway to Mid-2028 with $140M Offering, Reports Positive Clinical Data
ALXO has more than doubled off its 52-week low of $0.404 on elevated volume (4.7× avg).
Summary
ALX Oncology announced the completion of a $150 million equity offering, extending its cash runway through 1H 2028, alongside positive clinical biomarker data for evorpacept and progress in its pipeline.
Key Events · Financing and Capital Events · ALXO
-
Cash Runway Extended to Mid-2028
The company completed a registered equity offering, generating $140.4 million in net proceeds, which is expected to fund operations through the first half of 2028. This follows the pricing of the offering announced on January 30, 2026.
-
Positive Clinical Biomarker Validation
Exploratory analyses from Phase 2 ASPEN-06 (gastric cancer) and Phase 1b/2 (HER2-positive breast cancer) trials validated CD47 overexpression as a predictive biomarker for evorpacept response and durable benefit.
-
Pipeline Advancement and Trial Expansion
The Phase 2 ASPEN-09 breast cancer trial, evaluating evorpacept efficacy by CD47 expression, has expanded enrollment from 80 to up to 120 patients, with topline data anticipated mid-2027. The Phase 1 ALX2004 trial is also progressing, with safety data from the dose-escalation phase expected in 2H 2026.
-
Improved Financial Performance
ALX Oncology reported a GAAP net loss of ($22.8) million for Q4 2025 and ($101.7) million for the full year 2025, representing a decrease in losses compared to the prior year periods.
Analysis · ALXO · Life Sciences
ALX Oncology has significantly strengthened its financial position and clinical outlook. The completion of a $150 million public offering, yielding $140.4 million in net proceeds, extends the company's cash runway through the first half of 2028. This provides crucial funding for ongoing clinical programs, substantially de-risking the company's near-term operations. Concurrently, the company reported positive biomarker validation for its lead candidate, evorpacept, in multiple cancer trials, reinforcing its targeted development strategy. Progress in both evorpacept and ALX2004 clinical trials, coupled with reduced net losses, indicates a positive trajectory for the clinical-stage biotechnology firm.
At the time of this filing, ALXO was trading at $2.48 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $308.3M. The 52-week trading range was $0.40 to $2.66. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.